1204 related articles for article (PubMed ID: 24444771)
1. Psilocybin--summary of knowledge and new perspectives.
Tylš F; Páleníček T; Horáček J
Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771
[TBL] [Abstract][Full Text] [Related]
2. The pharmacology of psilocybin.
Passie T; Seifert J; Schneider U; Emrich HM
Addict Biol; 2002 Oct; 7(4):357-64. PubMed ID: 14578010
[TBL] [Abstract][Full Text] [Related]
3. [Hallucinogenic mushrooms].
Reingardiene D; Vilcinskaite J; Lazauskas R
Medicina (Kaunas); 2005; 41(12):1067-70. PubMed ID: 16401965
[TBL] [Abstract][Full Text] [Related]
4. DARK Classics in Chemical Neuroscience: Psilocybin.
Geiger HA; Wurst MG; Daniels RN
ACS Chem Neurosci; 2018 Oct; 9(10):2438-2447. PubMed ID: 29956917
[TBL] [Abstract][Full Text] [Related]
5. Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders.
Thomas K; Malcolm B; Lastra D
J Psychoactive Drugs; 2017; 49(5):446-455. PubMed ID: 28481178
[TBL] [Abstract][Full Text] [Related]
6. The Therapeutic Potential of Psilocybin.
Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L
Molecules; 2021 May; 26(10):. PubMed ID: 34063505
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
[TBL] [Abstract][Full Text] [Related]
8. [Classic psychedelic drugs and their potential therapeutic effect].
Bayat M
Ugeskr Laeger; 2017 Sep; 179(37):. PubMed ID: 28918777
[TBL] [Abstract][Full Text] [Related]
9. Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile.
Holze F; Singh N; Liechti ME; D'Souza DC
Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 May; 9(5):472-489. PubMed ID: 38301886
[TBL] [Abstract][Full Text] [Related]
10. [Hallucinogenic mushrooms in Denmark].
Holm JW; Ebbehøj NE; Fjeldberg IA
Ugeskr Laeger; 1997 Aug; 159(34):5116-8. PubMed ID: 9297322
[No Abstract] [Full Text] [Related]
11. A journey with psychedelic mushrooms: From historical relevance to biology, cultivation, medicinal uses, biotechnology, and beyond.
Pepe M; Hesami M; de la Cerda KA; Perreault ML; Hsiang T; Jones AMP
Biotechnol Adv; 2023 Dec; 69():108247. PubMed ID: 37659744
[TBL] [Abstract][Full Text] [Related]
12. Psilocybin: A brief overview for psychiatric mental health nurse practitioners.
Fradkin D
Perspect Psychiatr Care; 2022 Jul; 58(3):1200-1203. PubMed ID: 34101846
[TBL] [Abstract][Full Text] [Related]
13. Neuroimaging: a scanner, colourfully.
Roiser JP; Rees G
Curr Biol; 2012 Apr; 22(7):R231-3. PubMed ID: 22497939
[TBL] [Abstract][Full Text] [Related]
14. Human behavioral pharmacology of psychedelics.
Strickland JC; Johnson MW
Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
[TBL] [Abstract][Full Text] [Related]
15. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
[TBL] [Abstract][Full Text] [Related]
16. Molecular insights into psychedelic drug action.
Slocum ST; DiBerto JF; Roth BL
J Neurochem; 2022 Jul; 162(1):24-38. PubMed ID: 34797943
[TBL] [Abstract][Full Text] [Related]
17. Sustained effects of single doses of classical psychedelics in humans.
Knudsen GM
Neuropsychopharmacology; 2023 Jan; 48(1):145-150. PubMed ID: 35729252
[TBL] [Abstract][Full Text] [Related]
18. A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment.
Burdick BV; Adinoff B
Am J Drug Alcohol Abuse; 2013 Sep; 39(5):291-7. PubMed ID: 23968172
[TBL] [Abstract][Full Text] [Related]
19. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
Pearson C; Siegel J; Gold JA
J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
[TBL] [Abstract][Full Text] [Related]
20. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.
Johnson MW; Griffiths RR; Hendricks PS; Henningfield JE
Neuropharmacology; 2018 Nov; 142():143-166. PubMed ID: 29753748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
